Oxytocin Acetate

2mg Vial

5mg Vial

2 September 2026Updated 2 September 2026

Oxytocin Acetate

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Oxytocin Acetate.

Create free account Member login

Full range of benefits for Oxytocin Acetate

Stimulates uterine contractions during labor (uterotonic effect)

Used to prevent and treat postpartum hemorrhage

Promotes milk let-down and lactation by triggering milk ejection reflex

Facilitates maternal bonding and caregiving behaviours

Associated with increased social trust and prosocial interactions

May enhance recognition of social and emotional cues

Modulates stress response and can reduce cortisol in some studies

Has analgesic effects in childbirth and may reduce pain perception

Contributes to sexual arousal and orgasm-related responses

Influences cardiovascular function via vasodilation and blood pressure effects

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 14 known interactions

Synergistic(2)Compatible(3)Monitor(5)Avoid(4)

Generally well-tolerated alongside this peptide

Intravenous crystalloids (normal saline, Ringer's lactate)

Standard IV fluids are compatible and commonly co-administered to support intravascular volume during oxytocin therapy without direct pharmacologic interaction.

Paracetamol (acetaminophen)

Paracetamol provides analgesia and is pharmacologically neutral with oxytocin, requiring no dose adjustment.

Peripartum antibiotics (e.g., cefazolin)

Peri-partum antibiotics such as cefazolin are compatible with oxytocin and have no clinically significant interactions.

All interaction categories

Synergistic (2)

Prostaglandin analogs (misoprostol, dinoprostone): Prostaglandin analogs enhance uterine contractility and can synergistically augment labour induction or augmentation when used sequentially or in combination with oxytocin.
Tranexamic acid: Tranexamic acid reduces fibrinolysis and, when given alongside oxytocin for postpartum haemorrhage, synergistically decreases blood loss.

Compatible (3)

Intravenous crystalloids (normal saline, Ringer's lactate): Standard IV fluids are compatible and commonly co-administered to support intravascular volume during oxytocin therapy without direct pharmacologic interaction.
Paracetamol (acetaminophen): Paracetamol provides analgesia and is pharmacologically neutral with oxytocin, requiring no dose adjustment.
Peripartum antibiotics (e.g., cefazolin): Peri-partum antibiotics such as cefazolin are compatible with oxytocin and have no clinically significant interactions.

Monitor (5)

Magnesium sulfate: Magnesium sulfate used for pre-eclampsia can attenuate uterine responsiveness to oxytocin and requires monitoring of uterine activity and possible oxytocin dose adjustment.
Inhalational anaesthetics (isoflurane, sevoflurane): Volatile anaesthetics can cause uterine relaxation and reduce oxytocin efficacy, so uterine tone and bleeding should be closely monitored during anaesthesia.
Vasopressors (phenylephrine, ephedrine): Oxytocin can cause hypotension and tachycardia; concomitant use with vasopressors requires monitoring of blood pressure and cardiovascular status to guide dosing.
SSRIs/SNRIs (e.g., sertraline, venlafaxine): Because oxytocin has antidiuretic effects, concurrent use with SSRIs/SNRIs increases the risk of hyponatraemia and warrants monitoring of serum sodium.
Other uterotonics (methylergonovine, carboprost): Combined use of oxytocin with other uterotonics produces additive uterine effects and cardiovascular risks, necessitating monitoring of uterine tone and blood pressure.

Avoid (4)

Methylergonovine (ergot alkaloid): Methylergonovine can cause severe hypertension and vasospasm and should be used cautiously with oxytocin because of additive uterotonic and cardiovascular effects.
Beta‑adrenergic tocolytics (terbutaline, ritodrine): Beta‑agonist tocolytics pharmacologically oppose oxytocin's uterotonic action and should be carefully evaluated before coadministration due to antagonism and cardiopulmonary risks.
Thiazide diuretics: Thiazide diuretics increase the risk of hyponatraemia and volume changes that may be exacerbated by oxytocin's antidiuretic effects, so coadministration warrants caution.
Ergot derivatives (ergotamine, dihydroergotamine): Ergot derivatives share potent vasoconstrictive properties that increase the risk of hypertension and ischemic events when combined with oxytocin-related hemodynamic changes.